Promising Preclinical Data Underpins Buy Rating for IN8bio’s nsCAR Platform

Uy Ear, an analyst from Mizuho Securities, maintained the Buy rating on IN8bio (INAB – Research Report). The associated price target remains the same with $8.00.

Uy Ear has given his Buy rating due to a combination of factors surrounding IN8bio’s innovative non-signaling gamma-delta T cell CAR-T (nsCAR) platform, which has shown promising preclinical in vitro data. The INB-300 platform’s ability to selectively target leukemia cells while preserving healthy tissue is a significant advancement over traditional CAR-T therapies, which often struggle with the co-expression of targeted antigens on healthy cells. This selectivity is crucial because it could lead to higher dosing with reduced risk of on-target, off-target toxicity, particularly in myeloid leukemias and solid tumors.
Additionally, Uy Ear’s confidence is bolstered by the validation from Takeda’s preclinical data, which demonstrated complete tumor eradication in animal models of AML utilizing a similar approach. The nsCAR platform’s enhanced efficacy is further supported by the inclusion of membrane-bound IL-15, which has been shown to significantly increase the cytotoxic ability of the modified T cells against AML cell lines. With these data points, IN8bio is positioned to advance the nsCAR platform into IND-enabling studies, indicating a clear path towards clinical development and potential commercialization, which underpins the Buy rating.

In another report released on April 10, H.C. Wainwright also maintained a Buy rating on the stock with a $14.00 price target.

INAB’s price has also changed slightly for the past six months – from $1.009 to $1.100, which is a 9.02% increase.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

IN8bio (INAB) Company Description:

IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.